Articles tagged with Clinical Trials
A phase 2 clinical trial has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus. The study found that patients treated with deucravacitinib experienced significant improvements in disease activity, with response rates ranging from 34% to 58% compared to placebo.
Researchers report positive results from the first placebo-controlled trial of anifrolumab, a human monoclonal antibody targeting type I interferon receptor in patients with lupus. Treatment with anifrolumab was well-tolerated and sustained reduction in lupus disease activity.
A study by Osaka Metropolitan University found that teaching fall prevention using home floor plans reduced falls in older hospital patients by 97% compared to a control group. The intervention group had no falls within two months of discharge, while the control group experienced 7.7% falls.
The study aims to assess the effectiveness of recombinant Factor VIIa (rFVIIa) in decreasing bleeding in the brain of patients with intracerebral hemorrhage (ICH). ICH is a deadly stroke type with no effective treatment, and this trial seeks to improve outcomes.
A new study from the University of Bath has found that clinical trials on heated tobacco products (HTPs) are often biased, with many being funded or affiliated with the tobacco industry. This raises concerns about the validity of HTPs as a safer alternative to cigarettes.
The West Texas Pharmacology Core laboratory at TTUHSC will focus on two primary areas: drug development and pediatric cancer. The core aims to address obstacles in drug development, including limited pharmacology expertise for small biotech companies and low profitability for pediatric cancer drugs.
The Wyss Center's ABILITY system, a fully implantable brain-computer interface, records neural activity in sheep with high accuracy, decoding fine movement intention from small brain areas. The device is designed to improve quality of life and independence for people with severe paralysis.
Researchers developed a 'leapfrog design' to efficiently test new psychological interventions. This method allows for the quick identification of ineffective interventions and rapid integration of new findings, leading to faster optimization of existing treatments.
Researchers conducted the largest clinical trial to date of psilocybin, finding a statistically significant rapid reduction in symptoms of depression. The study suggests that COMP360 psilocybin with psychological support could be an effective treatment strategy for people with treatment-resistant depression.
A recent study found that restoring blood flow to the legs through bypass surgery or stent placement reduced pain and improved quality of life for people with peripheral artery disease (PAD). The Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia Trial enrolled 1,830 participants and foun...
The BEST-CLI trial found that patients who received Bypass had a 32% reduction in Major Adverse Limb Events and 65% fewer major re-interventions compared to Endo. Both treatments were effective, but individualized decision-making is crucial for optimal outcomes.
A randomized controlled trial found that oral ENT-01 significantly improves constipation and possibly neurological symptoms in persons with Parkinson disease. The treatment is safe for up to 25 days, with a dose-dependent effect that persists beyond the treatment period.
A new study found that long-term treatment with intravenous iron improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency. The treatment was associated with a significant benefit on reducing the risk of heart failure hospitalization and cardiovascular death.
Researchers at Brigham and Women's Hospital found that olpasiran, a small interfering RNA drug, significantly reduces lipoprotein(a) levels in patients with established cardiovascular disease. The treatment was associated with minimal serious side effects apart from injection site reactions.
A large clinical trial found that administering steroids during infant heart surgery did not improve post-operative outcomes compared to placebo. However, secondary analysis revealed a small net benefit for some infants, with lower odds of bleeding requiring another operation.
A new study has shown that SGLT-2 inhibitors, a type of diabetes medication, can decrease cardiovascular risk in adults with chronic kidney disease. The meta-analysis included results from 13 major clinical trials and found a 28% lower risk of worsening kidney disease and death from cardiovascular disease.
Researchers evaluated the safety and efficacy of NTLA-2001 in patients with transthyretin amyloid cardiomyopathy. The results showed significant reductions in circulating TTR protein levels, which were sustained for up to six months after treatment.
A clinical trial found that early use of ECMO devices did not improve outcomes for adults with rapidly deteriorating or severe cardiogenic shock. Participants who received immediate ECMO therapy showed similar clinical outcomes as those receiving early conservative therapy, including treatment with inotropes and vasopressors.
A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.
A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...
A computational study found that adding more than two stratification factors to a phase 2 trial can significantly reduce its statistical power, making it harder to detect a positive result. For modestly sized trials with 84 participants, using four or six stratification factors resulted in power decreases of 13% and 25%, respectively.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A multicentre clinical trial found that a single dose of COMP360 psilocybin significantly reduced depression symptoms in participants with treatment-resistant depression. The study, involving 233 participants, showed improved outcomes for those receiving the 25mg dose compared to the control group.
A study analyzing 16,083 colorectal biopsies found that 2.65% of rectal adenocarcinoma patients have mismatch repair deficiency, challenging earlier estimates. The analysis also highlighted the importance of screening at all ages for this condition.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
The Alpha Stem Cell Clinic will develop preclinical studies into early and later phase clinical trials with the goal of establishing advanced regenerative medicine treatments. The clinic will also foster greater collaboration with eight similar clinics across the state and educate the public about stem cell and related therapies.
A monoclonal antibody was found to be up to 88.2% effective at preventing malaria infection in healthy, non-pregnant adults during a six-month malaria season in Mali, Africa. The study suggests that this antibody could complement other measures to protect vulnerable groups from seasonal malaria.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.
A new study published in NEJM Evidence found that crossword puzzle training significantly improved cognitive function and daily activities, reducing brain shrinkage in individuals with mild cognitive impairment. The findings suggest that engaging with familiar activities like crossword puzzles may be more effective than computerized co...
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have successfully treated six children with relapsed and treatment-resistant B-ALL using CRISPR-edited T cells, achieving deep remission in four patients. The treatment has shown promise as a viable alternative to currently available treatments.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers at Tulane University have discovered that following a low-carbohydrate diet can lead to reduced hemoglobin A1c levels and improved fasting glucose levels among individuals with unmedicated diabetes and prediabetes. The study suggests that a low-carb diet may be a useful approach for preventing and treating Type 2 diabetes.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
A 6-month randomized clinical trial found that a low-carbohydrate diet intervention resulted in larger reductions in hemoglobin A1c (HbA1c) levels compared to usual diet among adults with elevated untreated HbA1c. The study suggests that this dietary approach may be useful for preventing and treating type 2 diabetes.
Dr. Christine E. Seidman, a renowned physician-scientist, has made groundbreaking discoveries in genetics and cardiomyopathy, leading to new pharmacological treatments. Her work has improved our understanding of disease risks and has led to unique targeted therapies.
A randomized clinical trial found that applying topical antibiotics to the upper digestive tract can improve survival rates in mechanically ventilated intensive care patients. The study, published in JAMA, also showed a significant reduction in new hospital-acquired infections.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
RedHill Biopharma's Talicia demonstrates high potential for H. pylori eradication while minimizing systemic antibiotic exposure, outperforming generic rifabutin regimens. Movantik data shows improved patient quality of life and symptom improvement in opioid-induced constipation.
A new drug combination of cefepime and enmetazobactam has been found to be more effective in treating complicated urinary tract infections and acute pyelonephritis than a standard treatment. The study showed that the new combination was successful in treating 79% of patients, compared to 58.9% for the conventional treatment.
Researchers have developed a drug compound that stops cancer cell growth in mice with little effect on normal healthy cells, making it potentially nontoxic for patients. The therapy targets the epidermal growth factor receptor gene, which is overexpressed in about half of all triple-negative breast cancer cases.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A new study from the University of South Australia found that severe vitamin D deficiency is associated with a higher risk of mortality. The research evaluated 307,601 records from the UK Biobank and found that individuals with low vitamin D levels had a significantly decreased risk of death over a 14-year follow-up period.
A recent study found that patients treated with the combination of chemoradiation therapy and immunotherapy in a phase 3 clinical trial did not experience significant safety concerns. The treatment regimen showed no significant increase in toxicity compared to standard trimodality therapy alone.
Researchers found that two-dose CoronaVac vaccination schedules, spaced 2 or 4 weeks apart, elicit similar immune responses against SARS-CoV-2 variants. The study suggests that either schedule can provide equal protection against COVID-19.
Adding stereotactic body radiation therapy (SBRT) to sorafenib significantly improves overall survival, progression-free survival, and time to tumor progression in patients with advanced hepatocellular carcinoma. SBRT was shown to be effective without increasing toxicity.
A Phase III trial found that hypo-fractionated whole breast irradiation (WBI) with concurrent boost is not inferior to conventional WBI with a sequential boost following lumpectomy in patients with high-risk, early-stage breast cancer. The study showed comparable effectiveness and toxicity outcomes between the two treatment options.
A randomized phase III trial shows that adding radiation therapy to systemic therapy can delay tumor progression and lengthen survival without compromising quality of life. The combination of SBRT and sorafenib appears more effective than the drug on its own.
A randomized phase III trial found that hypofractionated whole-breast radiation with concurrent boost is comparable to six weeks of treatment for patients with higher-risk disease, reducing tumor recurrence by 20-30%. The three-week course was non-inferior to the longer treatment in terms of tumor recurrence and cosmetic outcomes.
The NRG-HN004 trial found that radiotherapy with durvalumab did not improve progression-free survival or overall survival compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma who have a contraindication to cisplatin. The study highlighted the need for further research in this population.
A phase II clinical trial has demonstrated the effectiveness of nivolumab, an immune checkpoint inhibitor, in treating advanced cutaneous squamous cell carcinoma. The study found a significant response rate of 58.3% among patients who received nivolumab, supporting its use as a standard therapy for this disease.
A large clinical trial data analysis found that rates of locoregional recurrence are low regardless of regional node irradiation use. The study suggests a randomized clinical trial is required to answer the question of whether favorable-risk patients can safely skip RNI.
In a first-in-human trial, FLASH radiation treatment was found safe and effective for pain relief in patients with bone metastases. The study showed significant pain relief in 7 out of 10 patients, with minimal side effects.
A phase II trial suggests that radiation can reduce painful complications and hospitalizations, and possibly extend overall survival in patients with advanced cancers. The study found that treating asymptomatic lesions with radiation reduced skeletal-related events and extended overall survival compared to those who received no radiation.
A randomized, phase III clinical trial found that patients who receive technical explanations from medical physicists before treatment have lower anxiety levels and higher satisfaction rates. Medical physicist consults can significantly improve patient outcomes by reducing stress and anxiety related to radiation therapy.
A phase III clinical trial confirms the safety and efficacy of a moderately shortened course of radiation therapy for men with high-risk prostate cancer. The study found no significant differences in survival rates, side effects, or recurrence between 5-week and 8-week radiation therapy.